We are live on ! Find out more
EPIX

ESSA Pharma
EPIX

Delisted

EPIX was delisted on the 8th of October, 2025.

Back to rankings

10 hedge funds and large institutions have $23.6M invested in ESSA Pharma in 2016 Q4 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

1.9% more ownership

Funds ownership: 0% → 1.9% (+1.9%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

17% less funds holding

Funds holding: 12 → 10 (-2)

22% less capital invested

Capital invested by funds: $30.5M → $23.6M (-$6.83M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
–
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
+$40.5K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$4.35K
3
TRCT
Tower Research Capital (TRC)
New York
+$914

Top Sellers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
-$212K
2
BC
Boxer Capital
California
-$74K

EPIX Hedge Fund Activity: Q4 2016 in Review

10 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ESSA Pharma (EPIX) for Q4 2016, worth a combined $23.6M — down 22% from $30.5M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of EPIX and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Acuta Capital Partners, adding an estimated $40.5K. The largest seller was DAFNA Capital Management, cutting an estimated $212K.

  • 10 institutional investors held ESSA Pharma (EPIX) as of Q4 2016, down from 12 in Q3 2016.
  • Funds reported $23.6M of ESSA Pharma stock for Q4 2016, down 22% quarter-over-quarter.
  • 0 funds opened new ESSA Pharma positions in Q4 2016 and 2 closed out, a net change of -2 holders.
  • The largest ESSA Pharma buyer in Q4 2016 was Acuta Capital Partners, an estimated $40.5K added.
  • The largest ESSA Pharma seller in Q4 2016 was DAFNA Capital Management, an estimated $212K sold.

Based on aggregated 13F filings for Q4 2016.